Cited by 552Pharmaceutical Practices and Patient OutcomesDementia and Cognitive Impairment ResearchSchizophrenia research and treatment

Cognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis

Barker, Melinda J, Greenwood, Kenneth M, Jackson, Martin, Crowe, Simon F·2004·CNS Drugs

Abstract

Introduction While benzodiazepines are the most widely used psychotropic drugs, there are relatively few studies that have examined deficits in cognitive functioning after long-term use. The literature that is available is difficult to interpret due to conflicting results as well as a variety of methodological flaws.Objective To systematically evaluate and integrate the available research findings to determine the effect of long-term benzodiazepine use on cognitive functioning using meta-analytical techniques.Methods Thirteen research studies that employed neuropsychological tests to evaluate cognitive performance after long-term use of benzodiazepine medication met inclusion criteria. The neuropsychological tests employed in these 13 studies were each categorised as measuring one of 12 cognitive domains. Separate effect sizes were calculated for each of the 12 cognitive categories. Each study was only allowed to contribute one effect size to each cognitive category by averaging together the effect sizes from the same study if more than one type of test was used to measure a particular category. This strategy resulted in equal weight being given to each study per category, regardless of the number of tests in that category.Results The overall mean number of patients who were benzodiazepine users was 33.5 (SD +/- 28.9) and the mean number of controls was 27.9 (SD +/- 19.6). The duration of benzodiazepine use ranged from 1 to 34 (mean 9.9) years. Long-term benzodiazepine users were consistently more impaired than controls across all cognitive categories examined, with effect sizes ranging in magnitude from -1.30 to -0.42. The mean weighted effect size was -0.74 (SD +/- 0.25). None of the effect sizes had 95% CIs that spanned zero and, therefore, all of these effects were significant and different to zero.Conclusion Moderate-to-large weighted effect sizes were found for all cognitive domains suggesting that long-term benzodiazepine users were significantly impaired, compared with controls, in all of the areas that were assessed. However, this study has several limitations, one being that it includes a relatively small number of studies. Further studies need to be conducted; ideally, well designed, controlled studies that thoroughly investigate certain areas of cognitive functioning and present data in such a way so as to be amenable to inclusion in a meta-analysis. Incorporating the information from these studies into a larger meta-analysis would allow for a more thorough and statistically sound investigation of the effects of moderator variables. The observation that long-term benzodiazepine use leads to a generalised effect on cognition has numerous implications for the informed and responsible prescription of these drugs.

Integrity signals

Registry

Crossref · 10.2165/00023210-200418010-00004

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The citation lists haven’t been fetched yet

References 46 · Cited by 552

Authors
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F.
Affiliations
La Trobe University (AU)
Corresponding author
Jackson, Martin
Venue
CNS Drugs
Published
2004
Volume
18
Issue
1
Pages
37-48
ISSN
1172-7047 (ISSN-L)
OpenAlex
W2092531501
Cited by
552
References
46
Citations by year
2026: 32 · 2025: 24 · 2024: 23 · 2023: 13 · 2022: 21 · 2021: 20 · 2020: 31 · 2019: 26 · 2018: 37 · 2017: 42 · 2016: 28 · 2015: 39 · 2014: 34 · 2013: 28 · 2012: 23
FWCI
5.99
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • RMIT Research Repository (RMIT University Library) (submittedVersion)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
long-term benzodiazepine use, cognitive impairment, cognitive function, neuropsychological performance, benzodiazepine adverse effects, cognitive domain, effect size, moderators, benzodiazepine withdrawal, benzodiazepine dependence, benzodiazepine tolerance
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Attention, Benzodiazepines, Child, Cognition, Female, Humans, Intelligence Tests, Learning, Male, Middle Aged, Neuropsychological Tests, Prospective Studies, Psychomotor Performance, Time, Anti-Anxiety Agents, Reproducibility of Results

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review